Ocugen (OCGN) EBIT (2014 - 2026)
Ocugen posted quarterly EBIT of -$17.8 million for Q1 2026, down 23.02% year-on-year from -$23.2 million in Q1 2025, and down 4.97% on a QoQ basis from -$17.0 million in Q4 2025.
Ocugen (OCGN) has 13 years of EBIT data on file, last reported at -$17.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 23.02% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at -$66.3 million (down 16.15% YoY), and the FY2025 full-year result was -$62.9 million, down 14.9% from the prior year.
- EBIT for Q1 2026 stood at -$17.8 million, down from -$17.0 million in the prior quarter.
- Across five years, EBIT topped out at -$11.5 million in Q4 2023 and bottomed at -$25.1 million in Q3 2022.
- The 5-year median for EBIT is -$17.0 million (2025), against an average of -$17.1 million.
- The widest annual swing landed in 2022, when EBIT plunged 169.66%; it then surged 50.65% in 2023.
- A 5-year view of EBIT shows it stood at -$23.4 million in 2022, then jumped by 50.65% to -$11.5 million in 2023, then fell by 20.09% to -$13.8 million in 2024, then slipped by 22.8% to -$17.0 million in 2025, then dropped by 4.97% to -$17.8 million in 2026.
- The last three EBIT figures came in at -$17.8 million (Q1 2026), -$17.0 million (Q4 2025), and -$17.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -17.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -17.00 Mn |
| Sep 30, 2025 | -17.63 Mn |
| Jun 30, 2025 | -13.80 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Dec 31, 2024 | -13.84 Mn |
| Sep 30, 2024 | -13.25 Mn |
| Jun 30, 2024 | -15.45 Mn |
| Mar 31, 2024 | -12.22 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -23.36 Mn |
| Sep 30, 2022 | -25.11 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.57 Mn |
| Sep 30, 2021 | -10.79 Mn |
| Jun 30, 2021 | -25.61 Mn |
| Mar 31, 2021 | -7.06 Mn |
| Dec 31, 2020 | -3.81 Mn |
| Sep 30, 2020 | -10.18 Mn |
| Jun 30, 2020 | -3.37 Mn |
| Mar 31, 2020 | -3.93 Mn |
| Dec 31, 2019 | -4.28 Mn |
| Sep 30, 2019 | -2.71 Mn |
| Jun 30, 2019 | -2.33 Mn |
| Mar 31, 2019 | -4.84 Mn |
| Dec 31, 2018 | -5.69 Mn |
| Sep 30, 2018 | -2.40 Mn |
| Jun 30, 2018 | -7.28 Mn |
| Mar 31, 2018 | -6.09 Mn |
| Dec 31, 2017 | -6.03 Mn |
| Sep 30, 2017 | -5.71 Mn |
| Jun 30, 2017 | -6.37 Mn |
| Mar 31, 2017 | -6.83 Mn |
| Dec 31, 2016 | -7.91 Mn |
| Sep 30, 2016 | -6.65 Mn |
| Jun 30, 2016 | -7.96 Mn |
| Mar 31, 2016 | -7.80 Mn |
| Dec 31, 2015 | -8.31 Mn |
| Sep 30, 2015 | -8.04 Mn |
| Jun 30, 2015 | -7.59 Mn |
| Mar 31, 2015 | -7.87 Mn |
| Dec 31, 2014 | -6.54 Mn |
| Sep 30, 2014 | -14.94 Mn |
| Jun 30, 2014 | -6.01 Mn |
| Mar 31, 2014 | -5.17 Mn |